CONTACT: AdvanceMed Research 609-895-0735 email@example.com
FOR IMMEDIATE RELEASE
ADVANCEMED RESEARCH SEEKS PARTICIPANTS FOR NEW EARLY ALZHEIMER’S DISEASE STUDY
Lawrenceville, New Jersey – December 2, 2015 – AdvanceMed Research today announced it is actively recruiting participants for a clinical study designed to evaluate the safety and potential efficacy of an investigational medication to determine whether it slows the progression of symptoms of Alzheimer’s disease, such as problems with memory or thinking clearly.
“At AdvanceMed Research, we take great pride in our care of and commitment to people living with Alzheimer’s disease,” said Arnold Witte, MD. “This clinical study is an important step in our effort to find potentially meaningful treatments for this disease.”
Men and women between the ages of 50 and 85 who are currently experiencing problems with memory or thinking may be eligible to participate in the study, which will include questionnaires and interviews, physical examinations, MRI and PET scans, and other tests to monitor health. A full list of inclusion/exclusion criteria can be found at www.clinicaltrials.gov and then searching Biogen study number 221AD302. Participation will involve in-person visits to AdvanceMed Research once or twice per month and telephone interviews for up to four years. Those eligible to participate will be required to have a “study partner” who knows them well and is prepared to accompany them to certain visits and provide information to the AdvanceMed Research study team.
There are no costs associated with participation in this study, and assistance with travel-related expenses may be available.
Those who believe that they or a loved one may be eligible for participation in this study – or who would like more information about the study criteria – should contact AdvanceMed Research at 609-895-0735 OR ask@AdvanceMed.info
More about the Clinical Study [ENGAGE and/or EMERGE] is a global Phase 3 clinical study to assess the potential efficacy and safety of an investigational compound being developed for the treatment of Alzheimer’s disease. The trial is being conducted at approximately 150 sites in more than 20 countries in North America, Europe and Asia Pacific.
For more information, visit adacanumabclinicaltrials.com or clinicaltrials.gov (NCT02477800).
About Alzheimer’s Disease Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and behavioral disturbances that eventually result in a person’s inability to perform daily activities. An estimated 5.3 million Americans have Alzheimer’s disease . Evidence suggests that pathophysiological changes typically begin years prior to the symptoms that lead to a clinical diagnosis. As the disease progresses, cognitive impairments, behavioral changes and functional disability commonly associated with AD begin to manifest.
Helping a Loved One Cope with Common Problems in #EarlyAlzheimer's Depression – Symptoms of depression such as withdrawal, agitation, feelings of worthlessness, and changes in sleeping patterns are common among early stage Alzheimer's patients. Depression is treatable. Making the person feel safe and supported and creating a calm environment can help ease agitation and boost your loved one's outlook. Provide opportunities for your loved one to open up and talk about his or her fears and other emotions. ... See MoreSee Less
Seven stage model of #Alzheimer’s disease: Stage 4 – Late Confusional/Mild Alzheimer’s. Problems handling finances result from mathematical challenges. Recent events and conversations are increasingly forgotten, although most people in this stage still know themselves and their family. Problems carrying out sequential tasks, including cooking, driving, ordering food at restaurants, and shopping. Often withdraw from social situations, become defensive, and deny problems. Accurate diagnosis of Alzheimer’s disease is possible at this stage. Lasts roughly 2 years. ... See MoreSee Less